Developer docs
API playgroundTry for free, no card

Search company profiles

Blackstone Life Sciences

Full company profile

uuid0000cma

Namestring
Blackstone Life Sciences
Legal namestring
Blackstone Inc.
Websiteurl
blackstone.com
Company typeenum
Private
Founded yearint
2018
Descriptiontext

Blackstone Life Sciences (BXLS) is the dedicated life sciences investment business of Blackstone Inc. (NYSE: BX), focused on providing non-dilutive capital and development partnerships to pharmaceutical, biotechnology, and medical technology companies. The division was effectively created in December 2018 when Blackstone acquired Clarus, a healthcare-focused venture firm co-founded in 2005 by Dr. Nicholas Galakatos, who continues to lead BXLS as Global Head of Life Sciences and Chairman of its Investment Committees, alongside Senior Managing Director Ari Brettman, MD. BXLS operates from Cambridge, Massachusetts, with senior leadership co-located at Blackstone's New York headquarters at 601 Lexington Avenue, and serves a global enterprise client base spanning North America, Europe, the Middle East, and Asia.

BXLS delivers a modular platform of complementary financing instruments rather than a single product. Its core offering is the Blackstone Life Sciences VI fund (BXLS VI), which reached a final close at a record $6.3 billion hard cap in March 2026 — nearly 40% larger than its predecessor vehicle and the largest dedicated life sciences private fund ever raised. Around this fund vehicle, BXLS structures (i) Strategic Growth Capital Agreements — multi-year, milestone-tied funding deals exemplified by the $400 million Teva duvakitug agreement and the $700 million Merck sac-TMT R&D funding; (ii) Co-Funding Agreements for clinical development, including the Johnson & Johnson bleximenib partnership covering Phase 1–3 trials; (iii) structured Life Sciences Term Loans and Credit Facilities, such as the $570 million Axsome Therapeutics facility and the $100 million GeneDx term loan; (iv) Royalty Interest Investments, including the prior 50% LEQVIO royalty interest and the 1% AMVUTTRA interest subsequently sold to Royalty Pharma; and (v) a Company-Building / Ownership Strategy exemplified by the acquisition and build-out of Anthos Therapeutics around the abelacimab stroke-prevention therapy originally deprioritized at Novartis. Notably, BXLS-backed assets reportedly achieve an 85–86% Phase III approval success rate versus an industry average of approximately 48%.

The business model monetizes across multiple streams: (a) fund management fees and carried interest on the BXLS VI fund and prior vehicles, which collectively represent approximately $15 billion of platform assets; (b) milestone and royalty payments tied to regulatory and commercial outcomes on strategic growth capital and co-funding deals; (c) interest income and equity participation from term loan and credit facilities originated alongside Blackstone Credit & Insurance; and (d) gains from royalty monetization exits (e.g., the $310 million AMVUTTRA royalty sale) and portfolio company divestitures (e.g., the up to $3.1 billion Novartis acquisition of Anthos, with $925 million paid upfront). The customer base is overwhelmingly enterprise — large-cap pharma (Merck, Teva, J&J, Novartis, Alnylam) and mid-market biotech (Axsome, GeneDx) — accessed exclusively through senior, relationship-led direct engagement with C-suite and senior R&D / business development executives.

Short descriptiontext

Blackstone Life Sciences (BXLS) is the dedicated life sciences investment arm of Blackstone Inc., providing non-dilutive financing — strategic growth capital, royalty investments, term loans, and co-funding partnerships — to pharmaceutical and biotechnology companies developing late-stage therapeutics, backed by a record $6.3 billion flagship fund.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1,001–5,000
akta.pro rankint
HeadquartersCambridge, United States
HQ citystring
Cambridge
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
life sciences investment, biotech private equity, pharmaceutical R&D financing, royalty monetization, clinical development funding
Industry2 codes
PRIMARYFSANACAB
Healthcare & Life Sciences Growth Equity
SECONDARYFSAGAJAG
Treasury, Cash Management & Liquidity (SME)
Financial & Insurance/Financial Technology (Fintech)/B2B Fintech (SME Finance, Invoicing, Expense & Spend Management)
NAICS code2 codes
  • Portfolio Management and Investment Advice523940
  • Portfolio Management and Investment Advice52394
SIC code2 codes
  • Investment Advice6282
  • Security Brokers, Dealers & Flotation Companies6211
Product category
Life Sciences Investment Management
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1Royalty Monetization
TypeLicensing Royalties
Description

Generates revenue by acquiring royalty interests in approved or late-stage therapeutics (e.g., a 1% royalty interest in Alnylam's AMVUTTRA, sold to Royalty Pharma for $310 million) and monetizing them through sales to royalty buyers or capturing royalty streams over time.

globenewswire.com
2Strategic Growth Capital with Milestones and Royalties
TypeLicensing Royalties
Description

Provides multi-year strategic growth capital to pharma partners (e.g., $400M over four years to Teva for duvakitug; $700M to Merck for sac-TMT) in exchange for regulatory/commercial milestone payments and low single-digit royalties on worldwide sales.

webwire.com
3Structured Credit and Term Loans
TypeManaged Services
Description

Originates and provides term loans, revolving credit facilities, and structured credit to life sciences companies (e.g., $570M facility to Axsome Therapeutics with Blackstone Credit & Insurance; $100M term loan to GeneDx) earning interest income and equity participation.

blackstone.com
4Fund Management and Investment Returns
TypeManaged Services
Description

Raises dedicated life sciences private funds (BXLS VI at $6.3 billion) and deploys capital across new ventures and partnerships, generating carried interest, management fees, and investment returns on deployed capital.

benzinga.com
Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Others
Pricing details2 tiers
1Term loan facility (e.g., GeneDx $100M term loan at SOFR + 4.5% with 1.5% floor)
ModelOtherBilling cadenceMulti-year contract
Notes

Interest rate structured as SOFR plus 4.5 percent with a 1.5 percent floor; bespoke terms.

genomeweb.com
2Strategic growth capital with milestones and low single-digit royalties (e.g., $400M over four years for Teva duvakitug)
ModelOutcome Based/ PerformanceBilling cadenceMulti-year contract
Notes

$400M spread over four years; BXLS eligible for regulatory and commercial milestones plus low single-digit royalties on worldwide sales.

webwire.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Blackstone Life Sciences (BXLS) is the dedicated life sciences investment arm of Blackstone Inc., deploying capital through its BXLS VI fund ($6.3 billion) and complementary financing instruments — including strategic growth capital, co-funding of clinical trials, structured term loans and credit facilities, and royalty interest investments — to pharmaceutical, biotechnology, and medtech companies. It also pursues a company-building strategy by acquiring and developing companies around deprioritized drug assets. The platform pairs Blackstone's scale capital with deep scientific and clinical domain expertise, evidenced by an 85–86% Phase III approval success rate on BXLS-backed assets versus a ~48% industry average.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 85-86% Phase III approval success rate for BXLS-backed assets vs ~48% industry average
+4 more records
Product overview1 text field

Blackstone Life Sciences (BXLS) is not a software product but a single operating business unit of Blackstone that delivers a platform of complementary life sciences investment vehicles rather than one unified product. Its core offering is the Blackstone Life Sciences VI fund (BXLS VI, $6.3B), which sits alongside a set of modular financing instruments: Strategic Growth Capital Agreements (e.g., the $400M Teva duvakitug deal and the $700M Merck sac-TMT R&D funding), Co-Funding Agreements (e.g., the Johnson & Johnson bleximenib partnership), Life Sciences Term Loan and Credit Facilities (e.g., the $100M GeneDx term loan and the $570M Axsome facility), Royalty Interest Investments (e.g., the AMVUTTRA and LEQVIO royalty positions), and a Company-Building / Ownership Strategy exemplified by Anthos Therapeutics. These modules fit together as a continuum of non-dilutive financing spanning early clinical co-funding, late-stage development capital, structured debt, and post-approval royalty monetization.

Product and service6 records
1Blackstone Life Sciences VI (BXLS VI) Fund
CategoryPrivate life sciences fund
Description

Flagship dedicated life sciences private fund; raised $6.3B in capital commitments and committed nearly $2B in new investments over the prior 12 months with an 86% Phase III approval success rate. Capital is deployed across new ventures, partnerships, and biopharma/medtech financings through multiple instruments.

2Strategic Growth Capital Agreements
CategoryNon-dilutive R&D funding instrument
Description

Non-dilutive funding vehicles that BXLS deploys with pharmaceutical partners to share late-stage clinical development risk in exchange for milestone payments and royalties. Examples include the $400M, four-year Teva duvakitug agreement and the $700M Merck sac-TMT agreement supporting development through 2026.

3Co-Funding Agreements
CategoryClinical trial co-funding product
Description

Joint financing arrangements under which BXLS co-funds clinical trials alongside a pharmaceutical partner. The first such partnership is with Johnson & Johnson to advance bleximenib (oral menin inhibitor for AML) across Phase 1, 2, and 3 studies as monotherapy and in combination.

4Life Sciences Term Loan and Credit Facilities
CategoryStructured credit / debt financing
Description

Customized structured debt financing provided through Blackstone Life Sciences Advisors with Blackstone Credit & Insurance, including term loans, revolving credit facilities, and equity participation. Used by life sciences companies to refinance existing obligations and expand capital flexibility.

5Royalty Interest Investments
CategoryRoyalty monetization product
Description

Investments structured as royalty interests in approved or late-stage drug revenues, providing capital to pharma partners in exchange for a share of long-term product cash flows. Examples include BXLS's prior 1% royalty interest in Alnylam's AMVUTTRA and its 2020 $2B non-dilutive investment for a 50% royalty interest in LEQVIO.

6Company-Building / Ownership Strategy
CategoryPortfolio company acquisition and build-up
Description

BXLS's ownership strategy of acquiring or building companies around deprioritized pharmaceutical assets. The flagship example is the build-out of Anthos Therapeutics around the abelacimab stroke-prevention therapy (originally deprioritized at Novartis), which Novartis later reacquired for up to $3.1B.

Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-02-22
Description

Co-funding agreement with J&J to advance bleximenib (JNJ-75276617), an investigational oral menin inhibitor for acute myeloid leukemia (AML). Partners jointly finance Phase 1, 2, and 3 clinical trials as both monotherapy and in combination with AML-directed treatments for patients with KMT2A gene rearrangements or NPM1 mutations. Marked the first collaboration between the two organizations.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-04-03
Description

Novartis completed the acquisition of Anthos Therapeutics from Blackstone Life Sciences and Novo in a deal valued at up to $3.1 billion, with $925 million paid upfront. Anthos was built by BXLS around the Abelacimab stroke-prevention therapy, originally deprioritized at Novartis, before Novartis reacquired the company.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Largest dedicated acquirer of biopharmaceutical royalty interests; directly comparable to BXLS's royalty monetization strategy (BXLS sold its AMVUTTRA royalty interest to Royalty Pharma for $310M). Both deploy capital against approved and late-stage drug cash flows.

TypeDirect peer
Description

Dedicated life sciences private equity franchise of Bain Capital; comparable to BXLS in deploying scale capital across biotech, pharma and medtech with both control buyouts and structured non-control investments.

3EQT Life Sciences
TypeDirect peer
Description

EQT's life sciences investment platform (formerly LSP); operates growth and venture capital funds across biotech and medtech, directly comparable to BXLS's mix of development-stage capital and company-building.

TypeDirect peer
Description

Healthcare-dedicated private equity firm focused on biopharma and medtech; similar model of large-scale non-control and control life sciences investments targeting development-stage assets and strategic deals.

TypeDirect peer
Description

Specialist in structured financing and royalty/milestone monetization for biopharma; directly comparable to BXLS's royalty interest and strategic growth capital product lines.

TypeEmerging player
Description

Crossover and private life sciences investor with structured financing capabilities across PIPE, royalty and private equity transactions; overlaps with BXLS's late-stage development capital focus.

TypeBroad incumbent
Description

Growth-oriented healthcare strategy within KKR; comparable to BXLS as a large, diversified alternative asset manager with a dedicated life sciences/healthcare investment platform.

TypeBroad incumbent
Description

Carlyle's global healthcare private equity franchise; comparable as a large incumbent PE platform deploying capital into pharma, biotech and healthcare services across stages.

TypeBroad incumbent
Description

TPG's healthcare investment platform spans pharma services, biopharma and medtech; comparable as a broad incumbent alternative asset manager with material life sciences exposure.

TypeDirect peer
Description

Healthcare-dedicated investment firm across venture, growth, credit and royalty strategies; closely comparable to BXLS's multi-strategy life sciences platform, particularly its credit and structured financing capabilities.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment22 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Blackstone Life Sciences

Life Sciences Investment Managementblackstone.com

Blackstone Life Sciences (BXLS) is the dedicated life sciences investment arm of Blackstone Inc., providing non-dilutive financing — strategic growth capital, royalty investments, term loans, and co-funding partnerships — to pharmaceutical and biotechnology companies developing late-stage therapeutics, backed by a record $6.3 billion flagship fund.

What Blackstone Life Sciences does

Blackstone Life Sciences (BXLS) is the dedicated life sciences investment business of Blackstone Inc. (NYSE: BX), focused on providing non-dilutive capital and development partnerships to pharmaceutical, biotechnology, and medical technology companies. The division was effectively created in December 2018 when Blackstone acquired Clarus, a healthcare-focused venture firm co-founded in 2005 by Dr. Nicholas Galakatos, who continues to lead BXLS as Global Head of Life Sciences and Chairman of its Investment Committees, alongside Senior Managing Director Ari Brettman, MD. BXLS operates from Cambridge, Massachusetts, with senior leadership co-located at Blackstone's New York headquarters at 601 Lexington Avenue, and serves a global enterprise client base spanning North America, Europe, the Middle East, and Asia.

BXLS delivers a modular platform of complementary financing instruments rather than a single product. Its core offering is the Blackstone Life Sciences VI fund (BXLS VI), which reached a final close at a record $6.3 billion hard cap in March 2026 — nearly 40% larger than its predecessor vehicle and the largest dedicated life sciences private fund ever raised. Around this fund vehicle, BXLS structures (i) Strategic Growth Capital Agreements — multi-year, milestone-tied funding deals exemplified by the $400 million Teva duvakitug agreement and the $700 million Merck sac-TMT R&D funding; (ii) Co-Funding Agreements for clinical development, including the Johnson & Johnson bleximenib partnership covering Phase 1–3 trials; (iii) structured Life Sciences Term Loans and Credit Facilities, such as the $570 million Axsome Therapeutics facility and the $100 million GeneDx term loan; (iv) Royalty Interest Investments, including the prior 50% LEQVIO royalty interest and the 1% AMVUTTRA interest subsequently sold to Royalty Pharma; and (v) a Company-Building / Ownership Strategy exemplified by the acquisition and build-out of Anthos Therapeutics around the abelacimab stroke-prevention therapy originally deprioritized at Novartis. Notably, BXLS-backed assets reportedly achieve an 85–86% Phase III approval success rate versus an industry average of approximately 48%.

The business model monetizes across multiple streams: (a) fund management fees and carried interest on the BXLS VI fund and prior vehicles, which collectively represent approximately $15 billion of platform assets; (b) milestone and royalty payments tied to regulatory and commercial outcomes on strategic growth capital and co-funding deals; (c) interest income and equity participation from term loan and credit facilities originated alongside Blackstone Credit & Insurance; and (d) gains from royalty monetization exits (e.g., the $310 million AMVUTTRA royalty sale) and portfolio company divestitures (e.g., the up to $3.1 billion Novartis acquisition of Anthos, with $925 million paid upfront). The customer base is overwhelmingly enterprise — large-cap pharma (Merck, Teva, J&J, Novartis, Alnylam) and mid-market biotech (Axsome, GeneDx) — accessed exclusively through senior, relationship-led direct engagement with C-suite and senior R&D / business development executives.

Blackstone Life Sciences firmographics

Firmographics
Name
Blackstone Life Sciences
Legal name
Blackstone Inc.
Website
https://blackstone.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
1,001–5,000 employees
Short description
Blackstone Life Sciences (BXLS) is the dedicated life sciences investment arm of Blackstone Inc., providing non-dilutive financing — strategic growth capital, royalty investments, term loans, and co-funding partnerships — to pharmaceutical and biotechnology companies developing late-stage therapeutics, backed by a record $6.3 billion flagship fund.
Ownership category
akta.pro rank

Blackstone Life Sciences industry classification

Industry
Product category
Life Sciences Investment Management
NAICS
Portfolio Management and Investment Advice (523940), Portfolio Management and Investment Advice (52394)
SIC
Investment Advice (6282), Security Brokers, Dealers & Flotation Companies (6211)
akta.pro industry
PRIMARYFSANACAB
Healthcare & Life Sciences Growth Equity
SECONDARYFSAGAJAG
Treasury, Cash Management & Liquidity (SME)
Financial & Insurance/Financial Technology (Fintech)/B2B Fintech (SME Finance, Invoicing, Expense & Spend Management)

Keywords

  • Life sciences investment
  • Biotech private equity
  • Pharmaceutical R&D financing
  • Royalty monetization
  • Clinical development funding

Where Blackstone Life Sciences is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Blackstone Life Sciences business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Others

Revenue model

  1. Royalty Monetization: Generates revenue by acquiring royalty interests in approved or late-stage therapeutics (e.g., a 1% royalty interest in Alnylam's AMVUTTRA, sold to Royalty Pharma for $310 million) and monetizing them through sales to royalty buyers or capturing royalty streams over time.
  2. Strategic Growth Capital with Milestones and Royalties: Provides multi-year strategic growth capital to pharma partners (e.g., $400M over four years to Teva for duvakitug; $700M to Merck for sac-TMT) in exchange for regulatory/commercial milestone payments and low single-digit royalties on worldwide sales.
  3. Structured Credit and Term Loans: Originates and provides term loans, revolving credit facilities, and structured credit to life sciences companies (e.g., $570M facility to Axsome Therapeutics with Blackstone Credit & Insurance; $100M term loan to GeneDx) earning interest income and equity participation.
  4. Fund Management and Investment Returns: Raises dedicated life sciences private funds (BXLS VI at $6.3 billion) and deploys capital across new ventures and partnerships, generating carried interest, management fees, and investment returns on deployed capital.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractTerm loan facility (e.g., GeneDx $100M term loan at SOFR + 4.5% with 1.5% floor)
Outcome Based/ PerformanceMulti-year contractStrategic growth capital with milestones and low single-digit royalties (e.g., $400M over four years for Teva duvakitug)

Go-to-market motion1 record

Distribution channels1 record

Blackstone Life Sciences product offering

Product offering

Core offering

Blackstone Life Sciences (BXLS) is the dedicated life sciences investment arm of Blackstone Inc., deploying capital through its BXLS VI fund ($6.3 billion) and complementary financing instruments — including strategic growth capital, co-funding of clinical trials, structured term loans and credit facilities, and royalty interest investments — to pharmaceutical, biotechnology, and medtech companies. It also pursues a company-building strategy by acquiring and developing companies around deprioritized drug assets. The platform pairs Blackstone's scale capital with deep scientific and clinical domain expertise, evidenced by an 85–86% Phase III approval success rate on BXLS-backed assets versus a ~48% industry average.

Product overview

Blackstone Life Sciences (BXLS) is not a software product but a single operating business unit of Blackstone that delivers a platform of complementary life sciences investment vehicles rather than one unified product. Its core offering is the Blackstone Life Sciences VI fund (BXLS VI, $6.3B), which sits alongside a set of modular financing instruments: Strategic Growth Capital Agreements (e.g., the $400M Teva duvakitug deal and the $700M Merck sac-TMT R&D funding), Co-Funding Agreements (e.g., the Johnson & Johnson bleximenib partnership), Life Sciences Term Loan and Credit Facilities (e.g., the $100M GeneDx term loan and the $570M Axsome facility), Royalty Interest Investments (e.g., the AMVUTTRA and LEQVIO royalty positions), and a Company-Building / Ownership Strategy exemplified by Anthos Therapeutics. These modules fit together as a continuum of non-dilutive financing spanning early clinical co-funding, late-stage development capital, structured debt, and post-approval royalty monetization.

Differentiator

Problem solved

Functional benefit

Products and services

  • Blackstone Life Sciences VI (BXLS VI) Fund Flagship dedicated life sciences private fund; raised $6.3B in capital commitments and committed nearly $2B in new investments over the prior 12 months with an 86% Phase III approval success rate. Capital is deployed across new ventures, partnerships, and biopharma/medtech financings through multiple instruments.
  • Strategic Growth Capital Agreements Non-dilutive funding vehicles that BXLS deploys with pharmaceutical partners to share late-stage clinical development risk in exchange for milestone payments and royalties. Examples include the $400M, four-year Teva duvakitug agreement and the $700M Merck sac-TMT agreement supporting development through 2026.
  • Co-Funding Agreements Joint financing arrangements under which BXLS co-funds clinical trials alongside a pharmaceutical partner. The first such partnership is with Johnson & Johnson to advance bleximenib (oral menin inhibitor for AML) across Phase 1, 2, and 3 studies as monotherapy and in combination.
  • Life Sciences Term Loan and Credit Facilities Customized structured debt financing provided through Blackstone Life Sciences Advisors with Blackstone Credit & Insurance, including term loans, revolving credit facilities, and equity participation. Used by life sciences companies to refinance existing obligations and expand capital flexibility.
  • Royalty Interest Investments Investments structured as royalty interests in approved or late-stage drug revenues, providing capital to pharma partners in exchange for a share of long-term product cash flows. Examples include BXLS's prior 1% royalty interest in Alnylam's AMVUTTRA and its 2020 $2B non-dilutive investment for a 50% royalty interest in LEQVIO.
  • Company-Building / Ownership Strategy BXLS's ownership strategy of acquiring or building companies around deprioritized pharmaceutical assets. The flagship example is the build-out of Anthos Therapeutics around the abelacimab stroke-prevention therapy (originally deprioritized at Novartis), which Novartis later reacquired for up to $3.1B.

Quantifiable outcome

  • 85-86% Phase III approval success rate for BXLS-backed assets vs ~48% industry average
  • +4 more outcomes

Companies that use Blackstone Life Sciences

Customer profile

Named customers6 records

Ideal customer profiles2 records

Blackstone Life Sciences technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Blackstone Life Sciences partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered flagship and core.

  • Johnson & JohnsonflagshipStrategic or Co-development Partner · 22 February 2026Co-funding agreement with J&J to advance bleximenib (JNJ-75276617), an investigational oral menin inhibitor for acute myeloid leukemia (AML). Partners jointly finance Phase 1, 2, and 3 clinical trials as both monotherapy and in combination with AML-directed treatments for patients with KMT2A gene rearrangements or NPM1 mutations. Marked the first collaboration between the two organizations.
  • Novartis AGcoreStrategic or Co-development Partner · 3 April 2025Novartis completed the acquisition of Anthos Therapeutics from Blackstone Life Sciences and Novo in a deal valued at up to $3.1 billion, with $925 million paid upfront. Anthos was built by BXLS around the Abelacimab stroke-prevention therapy, originally deprioritized at Novartis, before Novartis reacquired the company.

Scale indicators11 records

Recent moves9 records

Expansion highlights6 records

Blackstone Life Sciences competitors and assessment

Company assessment

Direct peers

  • Royalty Pharma: Largest dedicated acquirer of biopharmaceutical royalty interests; directly comparable to BXLS's royalty monetization strategy (BXLS sold its AMVUTTRA royalty interest to Royalty Pharma for $310M). Both deploy capital against approved and late-stage drug cash flows.
  • Bain Capital Life Sciences: Dedicated life sciences private equity franchise of Bain Capital; comparable to BXLS in deploying scale capital across biotech, pharma and medtech with both control buyouts and structured non-control investments.
  • EQT Life Sciences: EQT's life sciences investment platform (formerly LSP); operates growth and venture capital funds across biotech and medtech, directly comparable to BXLS's mix of development-stage capital and company-building.
  • Patient Square Capital: Healthcare-dedicated private equity firm focused on biopharma and medtech; similar model of large-scale non-control and control life sciences investments targeting development-stage assets and strategic deals.
  • HealthCare Royalty Partners (HCRx): Specialist in structured financing and royalty/milestone monetization for biopharma; directly comparable to BXLS's royalty interest and strategic growth capital product lines.
  • OrbiMed Advisors: Healthcare-dedicated investment firm across venture, growth, credit and royalty strategies; closely comparable to BXLS's multi-strategy life sciences platform, particularly its credit and structured financing capabilities.

Emerging players

  • RA Capital Management: Crossover and private life sciences investor with structured financing capabilities across PIPE, royalty and private equity transactions; overlaps with BXLS's late-stage development capital focus.

Broad incumbents

  • KKR Health Care Strategic Growth: Growth-oriented healthcare strategy within KKR; comparable to BXLS as a large, diversified alternative asset manager with a dedicated life sciences/healthcare investment platform.
  • Carlyle Global Healthcare: Carlyle's global healthcare private equity franchise; comparable as a large incumbent PE platform deploying capital into pharma, biotech and healthcare services across stages.
  • TPG Capital — Healthcare: TPG's healthcare investment platform spans pharma services, biopharma and medtech; comparable as a broad incumbent alternative asset manager with material life sciences exposure.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Blackstone Life Sciences social profiles

Digital presence

Blackstone Life Sciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Blackstone Life Sciences leadership team

Management profile

Number of profiles

Profiles2 records

Blackstone Life Sciences subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Blackstone Life Sciences funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Blackstone Life Sciences M&A and investment

M&A and investment

M&A

Investments22 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Blackstone Life Sciences

What does Blackstone Life Sciences do?

Blackstone Life Sciences (BXLS) is the dedicated life sciences investment arm of Blackstone Inc., deploying capital through its BXLS VI fund ($6.3 billion) and complementary financing instruments — including strategic growth capital, co-funding of clinical trials, structured term loans and credit facilities, and royalty interest investments — to pharmaceutical, biotechnology, and medtech companies. It also pursues a company-building strategy by acquiring and developing companies around deprioritized drug assets. The platform pairs Blackstone's scale capital with deep scientific and clinical domain expertise, evidenced by an 85–86% Phase III approval success rate on BXLS-backed assets versus a ~48% industry average.

Is Blackstone Life Sciences a public or private company?

Blackstone Life Sciences is a private company. It is classified as corporate owned and is currently operating.

When was Blackstone Life Sciences founded?

Blackstone Life Sciences was founded in 2018. It employs 1,001 to 5,000 people.

Where is Blackstone Life Sciences based?

Blackstone Life Sciences is headquartered in Cambridge, United States, in the North America region.

How does Blackstone Life Sciences make money?

Four revenue lines are on record. Royalty Monetization is the primary driver. The others are strategic Growth Capital with Milestones and Royalties, structured Credit and Term Loans and fund Management and Investment Returns.

Who are Blackstone Life Sciences's main competitors?

Direct peers on record are Royalty Pharma, Bain Capital Life Sciences, EQT Life Sciences, Patient Square Capital, HealthCare Royalty Partners (HCRx) and OrbiMed Advisors. RA Capital Management is listed as an emerging player. Broad incumbents are KKR Health Care Strategic Growth, Carlyle Global Healthcare and TPG Capital — Healthcare.

Does Blackstone Life Sciences have an API?

No public API is recorded for Blackstone Life Sciences.

What industry is Blackstone Life Sciences in?

Blackstone Life Sciences's product category is Life Sciences Investment Management. Its primary akta.pro industry code is FSANACAB, Healthcare & Life Sciences Growth Equity, with a secondary code of FSAGAJAG, Treasury, Cash Management & Liquidity (SME). Its NAICS code is 523940 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
YahooJ&J bets $2.2B on Ollin’s vision loss drugJohnson & Johnson agreed to acquire Ollin Biosciences for $2.2 billion upfront and $1.1 billion in milestones, backing its OLN324 eye drug. Blackstone Life Sciences will contribute $750 million for Phase 3 testing in wet AMD and diabetic macular edema. The deal aims to compete with Roche's Vabysmo, though analysts question the drug's differentiation.Business Wire BlogBlackstone Life Sciences Announces $750 Million R&D Funding AgreementBlackstone announced $750 million in development funding to Johnson & Johnson for Phase 3 trials of OLN324, an investigational therapy for retinal vascular diseases. The funding covers wet AMD and diabetic macular edema, subject to J&J's acquisition of Ollin Biosciences. Blackstone is entitled to regulatory and sales milestone payments plus single-digit royalties.Stock TitanBlackstone Life Sciences' $750M J&J funding awaits closeBlackstone Life Sciences announced $750 million in development funding to Johnson & Johnson for the Phase 3 clinical program of OLN324, an investigational therapy for retinal vascular diseases. The funding follows the expected closing of the acquisition of Ollin Biosciences, with Blackstone entitled to regulatory and sales milestone payments and single-digit royalties.Pulse 2.0Pfizer: Up To $1.5 Billion Funding Agreement With Blackstone Life Sciences To Advance Monthly GLP-1 Obesity DrugPfizer and Blackstone Life Sciences signed a funding agreement to provide up to $1.5 billion through 2028 for developing berobenatide, a monthly GLP-1 agonist for obesity. Blackstone will receive milestone payments tied to U.S. regulatory approval and sales targets, while Pfizer retains full control. The deal supports Pfizer's cardiometabolic pipeline without selling ownership.MarketScreenerHealth Care Down, but not by Much, on Rotation Out of AI - Health Care RoundupHealth-care stocks fell less than the broad market as traders rotated out of AI into defensive sectors. Merck KGaA raised its 2026 sales forecast for the third time after reporting top-line growth, and Blackstone's Life Sciences agreed to pay up to $1.5 billion to help Pfizer develop a GLP-1 drug.MarketWatchHealth Care Down, but not by Much, on Rotation Out of AI - Health Care RoundupHealth-care stocks fell less than the broad market as traders rotated out of AI bets into defensive sectors. Merck KGaA raised its 2026 sales forecast for the third time after reporting top-line growth, and Blackstone's Life Sciences agreed to pay up to $1.5 billion to help Pfizer develop a GLP-1 drug.PMLiVEPfizer to receive up to $1.5bn in funding from Blackstone Life SciencesPfizer and Blackstone Life Sciences announced a co-funding agreement where Blackstone will pay up to $1.5bn of development costs for berobenatide until 2028. Pfizer plans to advance 20+ trials in 2026, including phase 3 studies. Blackstone will receive milestone-based payments if the drug gets US approval and reaches sales targets.Business Wire BlogPfizer and Blackstone Life Sciences Announce Strategic Funding Agreement for Obesity ProgramPfizer and Blackstone Life Sciences announced a strategic co-funding agreement under which Blackstone will pay up to $1.5 billion of development costs for berobenatide through 2028. Blackstone will receive milestone-based payments subject to regulatory approval and commercial sales milestones, with Pfizer retaining full control.FinancialContent Business PagePfizer and Blackstone Life Sciences Announce Strategic Funding Agreement for Obesity ProgramPfizer and Blackstone Life Sciences announced a strategic co-funding agreement under which Blackstone will pay up to $1.5 billion of development costs for berobenatide through 2028. Blackstone will receive milestone-based payments upon U.S. regulatory approval of monthly dosing and commercial sales milestones, with Pfizer retaining full control.Pulse 2.0Blackstone Life Sciences Announces $455 Million Collaboration With Boston Scientific To Develop VITALYST Heart PumpBlackstone Life Sciences and Boston Scientific announced a $455 million collaboration to co-fund development of the VITALYST temporary heart pump for cardiogenic shock. The agreement marks their first joint funding of a Boston Scientific medical technology, aiming to improve cardiac output and patient safety.